Nicotinamide Riboside for Patients With Early-Stage Parkinson Disease: The NOPARK Randomized Clinical Trial.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Brakedal Brage, Skeie Geir Olve, Derad Carlotta, Alstadhaug Karl Bjørnar, Anundskås Ingunn, Berven Haakon, Biermann Martin, Bjørnarå Kari Anne, Torres Cleuren Yamila N, Dalbro Solveig E J, Eidelberg David, Foldnes Kjartan, Fortes Gabriela, Haugarvoll Kristoffer, Herlofson Karen, Hustad Eldbjørg, HogenEsch Roelfien Ida, Johanson Gard Aasmund Skulstad, Johnsen Stein Harald, Kunszt Krisztina, Kverneng Simon, Labusau Aliaksei, Lie Ingeborg Haugesag, Lilleng Hallvard, Lundervold Katarina, Lundqvist Christofer, Ma Yilong, McCann Adrian, Njølstad Tormund Haugland, Pihlstrøm Lasse, Riemer Frank, Rognerud Anna Kaja, Sheard Erika, Simonsen Axel Meyer, Storm Eline, Svensen Magnus, Toker Lilah, Tunold Jon-Anders, Dölle Christian, Friede Tim, Tzoulis Charalampos
Аннотация
OBJECTIVE: To determine whether nicotinamide riboside improves clinical outcomes in Parkinson disease compared with placebo.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled, phase 3 clinical trial conducted at 11 centers in Norway. Eligible participants were patients aged 35 years or older with Parkinson disease diagnosed within 2 years before enrollment, Hoehn and Yahr disease stage less than 3, abnormal dopamine transporter scintigraphy findings confirming dopaminergic nigrostriatal denervation, and stable dopaminergic treatment before enrollment. Of 537 screened individuals, 410 were randomized from May 6, 2020, to June 20, 2024, and 393 were included in the primary analysis. Final follow-up was completed on June 19, 2025.
INTERVENTIONS: Patients were randomized to receive oral nicotinamide riboside, 500 mg twice daily (n = 206), or matching placebo (n = 204) for 52 weeks.
MAIN OUTCOMES AND MEASURES: The primary outcome was change from baseline to week 52 in the Movement Disorder Society Unified Parkinson Disease Rating Scale total score (MDS-UPDRS parts I-III; range, 0-236, with higher scores indicating more severe disease; clinically important differences for improvement and worsening, 6.7 and 5.2 points, respectively), analyzed using a mixed model for repeated measures. The 5 key secondary outcomes were the individual parts I, II, and III of the MDS-UPDRS; dopamine transporter single-photon emission computed tomography brain imaging findings; and the Non-Motor Symptoms Scale score (NMSS; range, 0-360, with higher scores indicating greater nonmotor symptom burden).
RESULTS: Among the 393 participants in the primary analysis, the mean age was 65.6 (SD, 9.4) years and 133 (34%) were female. At week 52, the total MDS-UPDRS score increased by 2.45 (95% CI, 0.80-4.10) points with nicotinamide riboside and decreased by 0.27 (95% CI, -1.95 to 1.40) points with placebo, yielding an adjusted mean difference of 2.72 points (95% CI, 0.47-4.98 points; P = .02), favoring placebo. Of the 5 prespecified key secondary outcomes, 4 showed no significant difference, but nonmotor symptom burden worsened more with nicotinamide riboside (NMSS score adjusted mean difference, 4.22 [95% CI, 1.07-7.37] points; P = .009). Serious adverse events occurred in 17 (8.3%) of 205 participants receiving nicotinamide riboside and 29 (14.1%) of 205 receiving placebo in the safety population.
CONCLUSIONS AND RELEVANCE: Among patients with early Parkinson disease, nicotinamide riboside treatment for 52 weeks did not improve clinical outcomes and was associated with worse clinical outcomes than placebo. These findings do not support nicotinamide riboside as a disease-modifying treatment for Parkinson disease.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03568968.